Ad
related to: therapeutics
Search results
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down to $16.19
ETF DAILY NEWS· 4 days agoNurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) gapped down before the market opened on Tuesday . Nurix Therapeutics shares last traded at $15.86 ...
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Zacks· 3 days agoBicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple...
Where Will Viking Therapeutics Be in 5 Years?
Motley Fool via Yahoo Finance· 2 days agoIf you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is...
NeuBase Therapeutics shareholder meeting fails again to get enough votes for dissolution -...
The Business Journals· 4 days agoNeuBase Therapeutics Inc.'s second attempt to get shareholder approval for its dissolution plan...
Investors Purchase High Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)
ETF DAILY NEWS· 4 days agoSarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) was the recipient of some unusual options trading on Tuesday. Traders bought 3,559 call options on the stock. This ...
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above Two Hundred Day Moving Average of $2.25
ETF DAILY NEWS· 6 days agoGalectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving ...
Fulcrum Therapeutics, Inc. Expected to Earn FY2024 Earnings of ($0.78) Per Share (NASDAQ:FULC)
ETF DAILY NEWS· 4 days agoFulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Fulcrum Therapeutics ...
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of “Moderate Buy” from...
ETF DAILY NEWS· 5 days agoNeumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) has received an average rating of “Moderate Buy” from the seven analysts that are currently covering the company ...
News Flash: Analysts Just Made A Notable Upgrade To Their PTC Therapeutics, Inc. (NASDAQ:PTCT)...
Simply Wall St. via Yahoo Finance· 5 days agoPTC Therapeutics, Inc. (NASDAQ:PTCT) shareholders will have a reason to smile today, with the...
Rila Therapeutics doses first cohort in Phase I CKD treatment trial
Clinical Trials Arena via Yahoo Finance· 6 days agoRila Therapeutics has dosed the first cohort of subjects in a Phase I clinical trial of RLA-23174, a...
